In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

Hyuk Sang Yoo, Osam Mazda, Hyeon Yong Lee, Jin Chul Kim, Seok Min Kwon, Jung Eun Lee, Ick Chan Kwon, Hesson Jeong, Yu Seok Jeong, Seo Young Jeong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalJournal of Controlled Release
Volume112
Issue number1
DOIs
Publication statusPublished - 2006 May 1
Externally publishedYes

Fingerprint

Emulsions
Human Herpesvirus 4
Genetic Therapy
Proinsulin
Plasmids
Blood Glucose
DNA
Insulin
Squalene
Intravenous Injections
Genes
Reference Values
Spleen
Kidney
Polymerase Chain Reaction
Lung
Injections
Liver

Keywords

  • Cationic emulsion
  • Diabetic
  • Gene therapy
  • Insulin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector. / Yoo, Hyuk Sang; Mazda, Osam; Lee, Hyeon Yong; Kim, Jin Chul; Kwon, Seok Min; Lee, Jung Eun; Kwon, Ick Chan; Jeong, Hesson; Jeong, Yu Seok; Jeong, Seo Young.

In: Journal of Controlled Release, Vol. 112, No. 1, 01.05.2006, p. 139-144.

Research output: Contribution to journalArticle

Yoo, HS, Mazda, O, Lee, HY, Kim, JC, Kwon, SM, Lee, JE, Kwon, IC, Jeong, H, Jeong, YS & Jeong, SY 2006, 'In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector', Journal of Controlled Release, vol. 112, no. 1, pp. 139-144. https://doi.org/10.1016/j.jconrel.2006.01.019
Yoo, Hyuk Sang ; Mazda, Osam ; Lee, Hyeon Yong ; Kim, Jin Chul ; Kwon, Seok Min ; Lee, Jung Eun ; Kwon, Ick Chan ; Jeong, Hesson ; Jeong, Yu Seok ; Jeong, Seo Young. / In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector. In: Journal of Controlled Release. 2006 ; Vol. 112, No. 1. pp. 139-144.
@article{b43e4a6aef2048f9a69b69f5ab8ea916,
title = "In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector",
abstract = "A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.",
keywords = "Cationic emulsion, Diabetic, Gene therapy, Insulin",
author = "Yoo, {Hyuk Sang} and Osam Mazda and Lee, {Hyeon Yong} and Kim, {Jin Chul} and Kwon, {Seok Min} and Lee, {Jung Eun} and Kwon, {Ick Chan} and Hesson Jeong and Jeong, {Yu Seok} and Jeong, {Seo Young}",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.jconrel.2006.01.019",
language = "English",
volume = "112",
pages = "139--144",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

AU - Yoo, Hyuk Sang

AU - Mazda, Osam

AU - Lee, Hyeon Yong

AU - Kim, Jin Chul

AU - Kwon, Seok Min

AU - Lee, Jung Eun

AU - Kwon, Ick Chan

AU - Jeong, Hesson

AU - Jeong, Yu Seok

AU - Jeong, Seo Young

PY - 2006/5/1

Y1 - 2006/5/1

N2 - A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

AB - A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

KW - Cationic emulsion

KW - Diabetic

KW - Gene therapy

KW - Insulin

UR - http://www.scopus.com/inward/record.url?scp=33645753059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645753059&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.01.019

DO - 10.1016/j.jconrel.2006.01.019

M3 - Article

C2 - 16530875

AN - SCOPUS:33645753059

VL - 112

SP - 139

EP - 144

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -